Also known as NOS2A, INOS
Nitric Oxide Synthase 2 (NOS2, also known as inducible NOS or iNOS) in cancer.
elevated NOS2 has been shown to predict poor outcome in cancer such as ER- breast cancer, glioma, melanoma, cervical, liver, ovarian, and pancreatic. Taken together, NOS2 may be one of the most powerful biomarker and predictors of poor prognosis and an ideal target for cancer therapy.
Many cancers exhibit upregulated NOS2 expression as part of the tumor-associated inflammatory response.
– Examples include colorectal, breast, lung, and some head and neck cancers, where the inflammatory microenvironment can drive NOS2 induction.
(Will delete Record if Target field = "Delete") Home